Christopher Hourigan, director of the Fralin Biomedical Research Institute Cancer Research Center D.C., was inducted this week into the American Society for
Virginia Tech professor inducted into medical honor society American Society for Clinical Investigation newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
Formerly a National Institutes of Health senior investigator who studies and treats blood cancer, Christopher Hourigan has joined Virginia Tech to lead cancer r
Retrospective, real-world results showed that patients treated with oral decitabine and cedazuridine and standard parenteral hypomethylating agents (HMAs) for myelodysplastic syndrome (MDS) demonstrated similar levels of comorbidities and disease burden to patients treated with intravenous (IV)/subcutaneous (SC) HMAs.
Oral decitabine/cedazuridine and parenteral hypomethylating agents were associated with similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.